PFIC

FTAI Aviation Ltd. Announces 2023 PFIC Annual Information Statement

Retrieved on: 
Thursday, March 21, 2024
QEF, Aviation, FTAI, PFIC

NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- FTAI Aviation Ltd. (“NASDAQ: FTAI”) is considered a Passive Foreign Investment Company (“PFIC”) for the taxable year ended on December 31, 2023.

Key Points: 
  • NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- FTAI Aviation Ltd. (“NASDAQ: FTAI”) is considered a Passive Foreign Investment Company (“PFIC”) for the taxable year ended on December 31, 2023.
  • If a U.S. Holder owns a PFIC, the U.S. Holder may be required to file a Form 8621.
  • U.S. Holders should consider making a Qualified Electing Fund (“QEF”) election with respect to FTAI.
  • FTAI will post a 2023 “PFIC Annual Information Statement” to its website at https://ir.ftaiaviation.com/tax-information .

Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer

Retrieved on: 
Monday, March 18, 2024
Sickle cell disease, University, Medicine, Doctor of Philosophy, Albireo, New Drug Application, Patient, SVP, Research, Losmapimod, Senior, Homocystinuria, Facioscapulohumeral muscular dystrophy, Therapy, DRS, Hereditary angioedema, Drug development, Interim, Boston, Fulcrum, PFIC, DSM-IV codes, Pharmaceutical industry

CAMBRIDGE, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced the appointment of Patrick Horn, M.D., Ph.D., as chief medical officer, effective immediately. Dr. Horn is a seasoned executive with over 20 years of end-to-end drug development experience spanning multiple therapeutic areas, with an emphasis on rare diseases, across both large pharmaceutical and biotech companies. Interim chief medical officer, Iain Fraser, MBChB, DPhil, will continue to serve on Fulcrum’s executive leadership team as SVP of early development. Together, Drs. Horn and Fraser will be responsible for leading clinical development and overseeing regulatory strategy and execution.

Key Points: 
  • Interim chief medical officer, Iain Fraser, MBChB, DPhil, will continue to serve on Fulcrum’s executive leadership team as SVP of early development.
  • Horn and Fraser will be responsible for leading clinical development and overseeing regulatory strategy and execution.
  • His most recent role was as the Chief Medical Officer at HemoShear Therapeutics, specializing in rare metabolic diseases.
  • Prior to transitioning to industry, Dr. Horn was a practicing pediatrician at major academic institutions in Chicago.

Mirum Pharmaceuticals’ LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada’s CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome

Retrieved on: 
Tuesday, April 2, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, Itch, Medication, Alagille syndrome, Liver disease, Inflammation, Patient, Cholestasis, Bile, Cholestatic pruritus, CADTH, Liver injury, The Hospital, Liver, CDEC, Genetic disorder, PFIC, Pharmaceutical industry

“The positive reimbursement recommendation for LIVMARLI by CADTH is an important step forward for patients suffering from the debilitating effects of cholestatic pruritus related to Alagille syndrome,” said Chris Peetz, chief executive officer at Mirum.

Key Points: 
  • “The positive reimbursement recommendation for LIVMARLI by CADTH is an important step forward for patients suffering from the debilitating effects of cholestatic pruritus related to Alagille syndrome,” said Chris Peetz, chief executive officer at Mirum.
  • These patients suffer greatly from the debilitating and disruptive effects of Alagille syndrome, which often starts in early childhood.”
    “CADTH’s recommendation of reimbursement for LIVMARLI provides a meaningful advancement in the treatment of cholestatic pruritus for patients with Alagille syndrome.
  • LIVMARLI is also approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the U.S. and Europe, and for Progressive Familial Intrahepatic Cholestasis (PFIC) in the U.S. and in Europe.
  • Cholestasis in ALGS is associated with pruritus which is among the most common indications for liver transplant in ALGS.

Galaxy Announces Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, March 26, 2024
International, Webcast, TSX, Depreciation, GDH, PFIC, Mining, Cryptocurrency

Hosted Mining Hashrate: the hashrate attributed to third-party machines operated by Galaxy for a client.

Key Points: 
  • Hosted Mining Hashrate: the hashrate attributed to third-party machines operated by Galaxy for a client.
  • Assets Under Stake: the total notional value of assets bonded to Galaxy validators, based on prices as of the end of the specified period.
  • As the only significant asset of GDH Ltd. is its minority interest in GDH LP, its results are driven by the results of GDH LP.
  • These consequences and, therefore, the need to take action apply to both direct and indirect holdings of Galaxy shares.

Tetragon Financial Group Limited U.S. Shareholders Tax Reporting Information

Retrieved on: 
Monday, March 18, 2024
QEF, PFIC, Security (finance)

Any such shareholders who wish to receive this confidential information should provide their contact details to Tetragon's Investor Relations department at the contact details below.

Key Points: 
  • Any such shareholders who wish to receive this confidential information should provide their contact details to Tetragon's Investor Relations department at the contact details below.
  • Tetragon will use reasonable efforts to provide information with respect to underlying portfolio companies that it has reasonably determined to be PFICs.
  • Although estimates of such underlying PFIC information may be provided earlier, Tetragon may not be able to provide actual underlying PFIC information in advance of the 15 April tax return deadline applicable to most individual U.S. taxpayers, and so such shareholders may wish to request an extension of their tax filing deadline.
  • In addition, Tetragon will not accept any liability for the accuracy or completeness of any such provided information.

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, February 28, 2024
Health, General Health, Research, Pharmaceutical, Science, Biotechnology, International, New Drug Application, FDA, Food, CTX, Growth, Primary sclerosing cholangitis, PDUFA, PFIC, Event, Food and Drug Administration, Primary biliary cholangitis, Webcast, Patient, Medication, NDA, Pharmaceutical industry

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for the fourth quarter and year-end 2023 and provided a business update.

Key Points: 
  • Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for the fourth quarter and year-end 2023 and provided a business update.
  • 2023 LIVMARLI net product sales totaled $141.8 million, representing approximately 89% growth over 2022 net product sales.
  • As of December 31, 2023, Mirum had cash and cash equivalents of $286.3 million.
  • The foregoing financial information is unaudited and subject to change, and actual results may vary from the foregoing.

Mirum Pharmaceuticals Announces Preliminary Unaudited 2023 Net Revenue and Provides Corporate Updates

Retrieved on: 
Monday, January 8, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, PFIC, Conference, Food, FDA, PDUFA, Medication, Disease, Disclosure, Growth, Webcast, Food and Drug Administration, Primary sclerosing cholangitis, Pharmaceutical industry

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today provided its preliminary and unaudited estimates for full-year 2023 revenue and net product sales, corporate updates, and full-year 2024 outlook.

Key Points: 
  • Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today provided its preliminary and unaudited estimates for full-year 2023 revenue and net product sales, corporate updates, and full-year 2024 outlook.
  • “2023 was a transformative year for Mirum as we cemented our position as a leader in rare disease and dramatically advanced our operating and financial scale.
  • Additional information and disclosure would be required for a more complete understanding of the company’s financial position and results of operations as of December 31, 2023.
  • Mirum will present at the 42nd annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 10, 2024 at 10:30 a.m. PT.

Belite Bio Reports Third Quarter 2023 Operational Highlights and Financial Results

Retrieved on: 
Tuesday, November 14, 2023
Stargardt disease, Visual acuity, Retina, QEF, Patient, PFIC, Therapy, Conference, Paratriathlon, Grade, Webcast, FAF, Safety, Food, ODD, RPD, Blood, RBP4, Eye, Adolescence, Exercise, Tissue, Vitamin A, University, AMD, DRAGON, Research, Ageing, Disease, FDA, Conference call, Westmead, Geographic atrophy, HIV disease progression rates, Pharmaceutical industry, Fine chemical, Citrus, Security (finance), Cryptocurrency, Stargardt, Hong Kong, PHOENIX, Ophthalmology

ET

Key Points: 
  • ET
    SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced its financial results for the three-months ended September 30, 2023, and provided a general business update.
  • “We made meaningful progress in the quarter advancing our clinical trials for Tinlarebant and are excited by our results,” said Dr. Tom Lin, Chairman and CEO of Belite Bio.
  • Third Quarter 2023 Financial Results:
    Cash: As of September 30, 2023, the Company had $54.5 million in cash.
  • Belite Bio will host a webcast on Tuesday, November 14, 2023, at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a business update.

VanEck Announces Year-End Distributions for VanEck Equity ETFs

Retrieved on: 
Saturday, December 16, 2023
Professional Services, Data Analytics, Other Professional Services, Finance, Asset Management, Consulting, ETF, Communication, Investment, Disclosure, Funding, Passive foreign investment company, Circular 230, IRS, Paul Ecke Ranch, PFIC

Passive Foreign Investment Company (PFIC) Income: Several VanEck ETFs may make investments in non-U.S. corporations classified as “passive foreign investment companies”.

Key Points: 
  • Passive Foreign Investment Company (PFIC) Income: Several VanEck ETFs may make investments in non-U.S. corporations classified as “passive foreign investment companies”.
  • Please refer to your VanEck ETF’s Statement of Additional Information (SAI) for further information on PFICs.
  • Shareholders or potential shareholders of the VanEck ETFs should obtain their own independent tax advice based on their particular circumstances.
  • If you have any questions concerning this information or the VanEck ETFs in general, please call 800.826.2333 between 9:00 am and 5:30 pm ET, Monday through Friday.

Mirum Pharmaceuticals Presents New Data at The Liver Meeting®

Retrieved on: 
Monday, November 13, 2023
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Infectious Diseases, Clinical Trials, Sleep, Hepatology, MDR3, Self-harm, Safety, Hepatocellular carcinoma, Bilirubin, Cholestasis, AASLD, Liver, Disease, Risk, Cholestatic pruritus, Hematology, Quality of life (healthcare), MYO5B, PFIC, Patient, Publication, Pregnancy, Nature, TJP2, Ascending cholangitis, GI, Hippeastrum mirum, Liver support system, Volixibat, ICP, IBAT, Progressive familial intrahepatic cholestasis, FIC, Augmented fifth, Growth, Doctor of Philosophy, Quality of life, AND, Itch, Medication, MCID, HIV disease progression rates, SBA, Chloride, Pharmaceutical industry, Nursing, Medical imaging, Dietary supplement, Boston, BSEP

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced new data from its LIVMARLI and volixibat programs presented at The Liver Meeting®, the American Association for the Study of Liver Diseases (AASLD) annual meeting in Boston, Massachusetts.

Key Points: 
  • Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced new data from its LIVMARLI and volixibat programs presented at The Liver Meeting®, the American Association for the Study of Liver Diseases (AASLD) annual meeting in Boston, Massachusetts.
  • “PFIC is a chronic, debilitating cholestatic liver disease characterized by elevated bile acids and pruritus so severe that patients can be listed for liver transplant even in the absence of disease progression.
  • These data suggest overall improved liver health with maralixibat treatment in patients with PFIC that can be maintained long-term.
  • No clinically meaningful changes in liver enzyme levels or hematology parameters were observed after volixibat treatment.